Fintel reports that on July 21, 2023, Needham reiterated coverage of Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) with a Buy recommendation.
Analyst Price Forecast Suggests 4.87% Downside
As of July 6, 2023, the average one-year price target for Recursion Pharmaceuticals Inc - is 14.72. The forecasts range from a low of 8.08 to a high of $34.65. The average price target represents a decrease of 4.87% from its latest reported closing price of 15.47.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Recursion Pharmaceuticals Inc - is 63MM, an increase of 34.96%. The projected annual non-GAAP EPS is -1.49.
What is the Fund Sentiment?
There are 337 funds or institutions reporting positions in Recursion Pharmaceuticals Inc -. This is an increase of 9 owner(s) or 2.74% in the last quarter. Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 37.81%. Total shares owned by institutions decreased in the last three months by 8.00% to 130,314K shares. 
The put/call ratio of RXRX is 0.59, indicating a bullish outlook.
What are Other Shareholders Doing?
Baillie Gifford holds 25,136K shares representing 12.56% ownership of the company. In it's prior filing, the firm reported owning 24,821K shares, representing an increase of 1.25%. The firm decreased its portfolio allocation in RXRX by 24.15% over the last quarter.
MIC Capital Management UK LLP holds 8,452K shares representing 4.22% ownership of the company. No change in the last quarter.
Kinnevik AB holds 7,653K shares representing 3.83% ownership of the company. No change in the last quarter.
Data Collective IV GP holds 5,941K shares representing 2.97% ownership of the company. No change in the last quarter.
Laurion Capital Management holds 4,826K shares representing 2.41% ownership of the company. No change in the last quarter.
Recursion Pharmaceuticals Background Information
(This description is provided by the company.)
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to its mission is the Recursion Operating System, or Recursion OS, that combines an advanced infrastructure layer to generate what Recursion believes is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that the company uses to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate its programs. biotechnology company scaling more like a technology company.
Additional reading:
- STOCK PURCHASE AGREEMENT BY AND BETWEEN RECURSION PHARMACEUTICALS, INC., THE PURCHASER AS SET FORTH HEREIN JULY 11, 2023 TABLE OF CONTENTS
- REGISTRATION RIGHTS AGREEMENT
- Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
- Early June 2023 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These forward-looking
- Registration Agreement dated May 25, 2023 by and among the Registrant, Recursion Canada Inc., and certain shareholders of Cyclica Inc.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
